In cooperation with the Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, and the Medical Faculty of the University of Magdeburg, glyXera participates in a project investigating the impact of SARS-CoV-2 spike S1 protein glycosylation on vaccine efficiency. In a press release of the Max Planck Society:

The scientists will first produce the spike S1 protein in insect cell cultures, specifically modify glycosylation using synthetic biotechnology methods, and investigate the immune response in mice. If it turns out that a spike S1 protein with a specific sugar envelope prepares the immune system particularly well for an infection with Sars-CoV-2, this could help the scientists to develop an effective vaccine.

The glycoanalytics in this project will be conducted by glyXera GmbH.

For more details, see the official press release of the Max Planck Society.